KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 112 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q4 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,054,359 | +23.4% | 60,700 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $854,656 | +18.4% | 60,700 | -9.5% | 0.00% | – |
| Q1 2023 | $721,996 | -35.7% | 67,100 | -10.4% | 0.00% | -100.0% |
| Q4 2022 | $1,122,002 | +20.9% | 74,900 | +3.6% | 0.00% | 0.0% |
| Q3 2022 | $928,000 | +32.4% | 72,300 | 0.0% | 0.00% | – |
| Q2 2022 | $701,000 | +17.4% | 72,300 | +20.3% | 0.00% | – |
| Q1 2022 | $597,000 | -3.9% | 60,100 | +13.8% | 0.00% | – |
| Q4 2021 | $621,000 | +3.3% | 52,800 | 0.0% | 0.00% | – |
| Q3 2021 | $601,000 | -18.3% | 52,800 | 0.0% | 0.00% | – |
| Q2 2021 | $736,000 | -26.6% | 52,800 | -2.6% | 0.00% | -100.0% |
| Q1 2021 | $1,003,000 | +8.1% | 54,200 | +3.2% | 0.00% | 0.0% |
| Q4 2020 | $928,000 | +15.4% | 52,500 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $804,000 | -18.3% | 52,500 | +36.0% | 0.00% | 0.0% |
| Q2 2020 | $984,000 | +492.8% | 38,600 | +97.9% | 0.00% | – |
| Q3 2019 | $166,000 | -37.1% | 19,500 | 0.0% | 0.00% | – |
| Q2 2019 | $264,000 | – | 19,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |